Eleana Vasileiadi, MD
About Eleana Vasileiadi, MD
Titles
Fellow
Leadership and Memberships
Memberships in Professional Organizations
International
Athens Medical Association
National
American Academy of Pediatrics
American Medical Association
Education & training
Medical Degree
MD - University of Athens School of Health Sciences, Greece
Residency
Pediatrics - SUNY Downstate Medical Center, Brooklyn, NY
Fellowship
Infectious Diseases - Children's Hospital of Philadelphia, Philadelphia, PA
Publications
Publications
2019
C, D., & Zhang, D., & Stashko, M., & Vasileiadi, E., & Parker, R., & Minson, KA., & Huey, MG., & Huelse, J., & Hunter, D., & Gilbert, TSK., & Norris-Drouin, J., & Miley, M., & Herring, LE., & Graves, LM., & DeRyckere, D., & Earp, HS., & Graham, DK. Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology. Journal of Medicinal Chemistry. (2019); 141(39): 15700-15709. Cited in PubMed; PMID: 31497954.
2018
McDaniel, N.K., & Cummings, T.K., & Iida, M., & Hulse, J., & Pearson, H.E., & Vasileiadi, E., & Parker, R.E., & Orbuch, R.A., & Ondracek, O.J., & Welke, N.B., & Kang, G.H., & Davies, K.D., & Wang, X., & DeRyckere, D., & Graham D.K., & Wheeler D.K. MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents. Molecular Cancer Therapeutics. (2018); 17(11): 2297-2308. Cited in PubMed; PMID: 30093568.
Smart, S.K., & Vasileiadi, E., & Wang, X., & DeRyckere, D., & Graham, DK. The Emerging Role of TYRO3 as a Therapeutic Target in Cancer. Cancers (Basel). (2018); 10(12): 474.Cited in PubMed; PMID: 30501104.
Zhao, J., & Zhang, D., & zhang, w., & Stashko, M., & DeRyckere, D., & Vasileiadi, E., & Parker, R., & Hunter, D., & Liu, Q., & Zhang, Y., & Norris-Drouin, J., & Drewry, D., & Kireev, D., & Graham, D., & Earp, H., & Frye, S.V., & Wang, X. Highly selective MERTK inhibitors achieved by a single methyl group. Journal of Medicinal Chemistry.(2018); 61(22): 10242-10254. Cited in PubMed; PMID: 30347155.